V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Perez, Lautaro G ^a   Martinez, David R ^a   DeCamp, Allan C ^b   Pinter, Abraham ^c   Berman, Phillip W ^d   Francis, Donald ^e   Sinangil, Faruk ^e   Lee, Carter ^e   Greene, Kelli ^a   Gao, Hongmei ^a   Nitayaphan, Sorachai ^f   Rerks Ngarm, Supachai ^g   Kaewkungwal, Jaranit ^h   Pitisuttithum, Punnee ^h   Tartaglia, James ⁱ   O'Connell, Robert J ^f,j   Robb, Merlin L ^j   Michael, Nelson L ^j   Kim, Jerome H ^k   Gilbert, Peter ^b   Montefiori, David C ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b USA   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d University of California Santa Cruz   (United States)

^e Global Solutions for Infectious Diseases   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ SANOFI PASTEUR   (France)

^j WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^k International Vaccine Institute   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANARYPOX VIRUS VECTOR; COMPLEMENT COMPONENT C3D; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG; V1V2 IMMUNOGLOBULIN G; VIRUS VECTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; CASE CONTROL STUDY; CLADISTICS; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; MALE; PROTECTION; RISK ASSESSMENT; RISK REDUCTION; AMINO ACID SEQUENCE; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; COMPLEMENT ACTIVATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G;

EID: 85022035434     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0180720     Document Type: Article

References (52)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.https://doi.org/10.1056/NEJMoa0908492 PMID: 19843557.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. (2012) Immune correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. https://doi.org/10.1056/NEJMoa1113425 PMID: 22475592.
3. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. (2010) Vaccineinduced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE 9(2): e87572. https://doi.org/10.1371/journal.pone.0087572 PMID: 24504509
4. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, et al. (2013) Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 8(9): e75665. https://doi.org/10.1371/journal.pone.0075665 PMID: 24086607
5. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6: 228ra239.
6. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. (2012) The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retrovir 11: 1444-1457. PMID: 23035746. https://doi.org/10.1089/aid.2012.0103
7. Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, et al. (2013) Analysis of V2 antibody responses induced in vaccines participating in the ALVAC/AIDSVAX HIV-1 clinical vaccine trial. PLOS ONE 8(1): e53629. https://doi.org/10.1371/journal.pone.0053629 PMID: 23349725.
8. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. https://doi.org/10.1038/nature11519 PMID: 22960785.
9. Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, de Camp AC, et al. (2015) Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comp Biol 11(2): e1003973. https://doi.org/10.1371/journal.pcbi.1003973
10. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206:431-441. https://doi.org/10.1093/infdis/jis367 PMID: 22634875.
11. Tomaras GD, Haynes BF (2014) Advancing toward HIV-1 vaccine efficacy through the intersections of immune Correlates. Vaccines (Basel) 2: 15-35.
12. McMichael AJ1, Haynes BF. (2012) Lessons learned from HIV-1 vaccine trials: new priorities and directions.Nat Immunol 13(5):423-7. https://doi.org/10.1038/ni.2264 PMID: 22513323
13. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. (2014) Polyfunctional Fceffector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6: 228ra238.
14. Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G,Thomas R, et al. (2014) FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest 124: 3879-3890. https://doi.org/10.1172/JCI75539 PMID: 25105367
15. Liao H-X, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, et al. (2013) Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38: 176-186. https://doi.org/10.1016/j.immuni.2012.11.011 PMID: 23313589.
16. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12 PMID: 22896626
17. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, et al. (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110: 9019-9024. https://doi.org/10.1073/pnas.1301456110 PMID: 23661056
18. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, et al. (2014) HIV-1 Vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88: 7715-7726.https://doi.org/10.1128/JVI.00156-14 PMID: 24807721
19. Nesargikar PN, Spiller B, Chavez R. (2012) The complement system: history, pathways and inhibitors.Eur J Microbiol Immunol 2(2): 103-111. PMCID: PMC3956958
20. Montefiori DC. (1996) Role of complement in HIV and SIV pathogenesis and immunity. Symposium in Immunology V: Antiviral Immunity, (Eible MM, Huber C, Peter HH, Wahn U, eds.) Springer-Verlag, Heidelberg, Germany, pp 31-53.
21. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. 2008. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 26:3046-3054. https://doi.org/10.1016/j.vaccine.2007.12.003 PMID: 18191309
22. Yu Q, Yu R, Qin X. 2010. The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 7:334-340. https://doi.org/10.1038/cmi.2010.8 PMID: 20228834
23. Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, et al. (1996) Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 157:1791-1798. PMID: 8759769
24. Sullivan BL, Takefman DM, Spear GT. (1998) Complement can neutralize HIV-1 plasma virus by a C5- independent mechanism. Virology 248:173-181. https://doi.org/10.1006/viro.1998.9289 PMID: 9721226
25. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, et al. (2005) Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79:2823-2830. https://doi.org/10.1128/JVI.79.5.2823-2830.2005 PMID: 15709001
26. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederöst B, et al. (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.PLoS Med 2006, 3:e441. https://doi.org/10.1371/journal.pmed.0030441 PMID: 17121450
27. Robinson WE Jr, Montefiori DC, Mitchell WM. (1988) Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet i:790-794.
28. Robinson WE Jr, Montefiori DC, Mitchell WM. (1990) Complement-mediated, antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 175:600-604.PMID: 2327077
29. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, et al. (1991) Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. J Acquir Immune Defic Syndr 5:269.
30. Gras G, Richard Y, Roques P, Olivier R, Dormont D (1993) Complement and virus-specific antibody dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 81:1808. PMID: 8461467
31. Toth FD, Mosborg-Petersen P, Kiss J, Aboagye-Mathiesen G, Zdravkovic M, Hager H, et al. (1994) Antibody-dependent enhancement of HIV-1-infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 96:389 PMID: 8004808
32. Robinson WE, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM (1990) Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-l-infection in vitro. J Virol 64:5301 PMID: 1698995
33. Robinson WE, Gorny MW, Xu J-Y, Mitchell WM, Zolla-Pazner S (1991) Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 65:4169 PMID: 2072448
34. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, et al. (1996) Neutralizing and infection- enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.J Infect Dis 173:60 PMID: 8537683
35. Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, et al. (2011) Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology 8:16. https://doi.org/10.1186/1742-4690-8-16 PMID: 21401915
36. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR. (1994) Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82-92. https://doi.org/10.1006/viro.1994.1622 PMID: 7526538
37. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. (1997) Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78:1907-1911. https://doi.org/10.1099/0022-1317-78-8-1907 PMID: 9266986
38. Pinter C, Siccardi AG, Longhi R, Clivio A. (1995) Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 11: 577-588. PMID: 7576914
39. Stoiber H, Pinté r C, Siccardi AG, Clivio A, Dierich MP. (1996) Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183(1):307-10. PMID: 8551237
40. Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM. (1994) Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor, CR1 (CD35), and red blood cells in the presence of envelope-specific antibodies and complement. J Infect Dis 170:429-432. PMID: 8035031
41. Zhou JT, Montefiori DC. (1996) Complement-activating antibodies that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1/CD35). Virology 226:13-21. https://doi.org/10.1006/viro.1996.0623 PMID: 8941318
42. Montefiori DC, Zhou JT, and Shaff DI. (1992) CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exp Immunol 90:383-389.PMID: 1360879
43. Montefiori DC, Stewart K, Ahearn JM, Zhou JT, Zhou JY. (1993) Complement-mediated binding of naturally glycosylated and glycosylation-modified HIV-1 to CR2 (CD21). J Virol 67:2699-2706. PMID: 8474169
44. Tremblay M, Meloche S, Sekaly RP, Wainberg MA (1990) Complement receptor type 2 mediates enhancement of human immunodeficiency virus type 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 171:1791. PMID: 2159052
45. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injecting drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. https://doi.org/10.1086/508748 PMID: 17109337.
46. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. (2005) Placebo-controlled phase 3 trial of recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665. https://doi.org/10.1086/428404 PMID: 15688278.
47. DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. (2014) Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88:2489-2507. https://doi.org/10.1128/JVI.02853-13 PMID: 24352443
48. Kayman SG, Wu Z, Revesz K, Chen H-C, Kopelman R, Pinter A. (1994) Presentation of native epitopes in the Vl/V2 and V3 domains of HIV-1 gp120 by fusion glycoproteins containing fragments of gp120. J Virol 68:400-410. PMID: 7504740
49. Montefiori DC. (2009) Measuring HIV neutralization in a luciferase reporter gene assay. HIV Protocols: Second Edition, Methods in Molecular Virology (Prasad Vinayaka R., Kalpana Ganjam V., eds.), Humana Press, 485:395-405.
50. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, et al. (2013) Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest 123(5):2218-2230. https://doi.org/10.1172/JCI65861 PMID: 23619360
51. Heyman B, Wiersma EJ, Kinoshita T (1991) In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med 172:665-672
52. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-350 PMID: 8553069